( May 22, 2026, 12:21 PM EDT) -- WASHINGTON, D.C. — A Federal Circuit U.S. Court of Appeals panel on May 21 affirmed a Delaware federal judge’s finding that a biopharmaceutical company’s patents related to a medication to treat kidney disease were not infringed by other biopharmaceutical companies’ filing for approval of a generic version of the drug by adding more than the claimed amount of a specific molecule to the generic version....